Developer docs
API playgroundTry for free, no card

Search company profiles

Vasant Chemicals

Full company profile

uuid002m8ut

Namestring
Vasant Chemicals
Legal namestring
Vasant Chemicals Pvt Limited
Company typeenum
Private
Founded yearint
1980
Descriptiontext

Vasant Chemicals Private Limited is an Indian specialty fine chemicals Contract Development and Manufacturing Organization (CDMO) headquartered in Hyderabad, with manufacturing operations in Hyderabad (Jeedimetla Unit) and Visakhapatnam (Achutapuram SEZ Unit). Founded in 1980, the company operates four interconnected product lines: Specialty Chemicals (catalysts, cosmetic additives, photo initiators for UV curing and 3D printing, grafted polymers for food packaging), Pharmaceutical Intermediates (serving 18+ therapeutic areas including anti-retroviral, anti-hypertensive, anti-Alzheimer, anti-migraine, and anti-cancer applications), Custom Manufacturing (scale-up from kilograms to multi-tonne quantities, with or without customer IP), and Catalysts & Polymers. The company maintains 950+ metric tonnes/year of commercial production capacity, >400KL installed reactor capacity, and 750,000+ litres of total production scale.

The company's underlying technology centers on chemical synthesis with extensive reaction capabilities (Bechamp reduction, Bromination, Cyclisation, Chloro Sulphonation, Catalytic Hydrogenation, Grignard reaction, and over 15 other specialized reactions), supported by kilo-lab, pilot plant, and commercial-scale infrastructure including high vacuum distillation with De Dietrich columns, biological treatment plants, and Zero Liquid Discharge (ZLD) systems. Vasant Chemicals is ISO 9001, 14001, and 45001 certified across both manufacturing sites, GMP-compliant, and DSIR-recognized for R&D.

The business model is B2B enterprise field sales with quote-based, multi-year contracts. Pharma intermediates are supplied under long-term exclusive and non-exclusive agreements with strategic multinational clients, while custom manufacturing engagements span both proprietary process development and customer IP-based production. Revenue streams derive from custom manufacturing services, pharma intermediate sales, specialty chemical sales, and catalyst/polymer sales. The company sells globally, with historical recognition including a Best Quality Supplier Award from Sandoz Chemicals USA (now Clariant) and export awards from CHEMEXCIL and the President of India. In March 2024, Vasant Chemicals was acquired by International Chemical Investors Group (ICIG) and now operates as part of the WeylChem Group's CDMO network, with a new Managing Director appointed to drive integration.

Short descriptiontext

Vasant Chemicals is an Indian specialty fine chemicals CDMO manufacturing pharmaceutical intermediates and specialty chemicals (catalysts, polymers, cosmetic additives, photo initiators) for global multinational clients across 18+ therapeutic areas, operating as part of the WeylChem Group following its 2024 ICIG acquisition.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty chemicals manufacturing, pharmaceutical intermediates, custom chemical synthesis, CDMO services, catalysts and polymers
Industry3 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code3 codes
  • Chemical Manufacturing325
  • Medicinal and Botanical Manufacturing325411
  • All Other Chemical Product and Preparation Manufacturing32599
SIC code3 codes
  • Industrial Organic Chemicals2860
  • Medicinal Chemicals & Botanical Products2833
  • Miscellaneous Chemical Products2890
Product category
Specialty Chemicals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Custom Manufacturing Services
TypeProfessional Services
Description

Custom synthesis and manufacturing services for pharmaceutical intermediates and specialty chemicals. Operations conducted both with and without customer-provided know-how and intellectual property. Scale-up capabilities from kilograms to multi-tonne quantities.

vasantchemicals.com
2Pharmaceutical Intermediates
TypeOne Time License
Description

Manufacturing of pharma intermediates used in 18+ therapeutic areas including Cancer Treatment, CNS, Anti-depressant, and Anti-retroviral applications. Products supplied under long-term contractual agreements with strategic clients on exclusive/non-exclusive basis.

vasantchemicals.com
3Specialty Chemicals
TypeOne Time License
Description

Innovative specialty chemicals for dyestuff, agrochemicals, electronic applications, cosmetic industry, colour accelerator and other industries. Products include catalysts, cosmetic additives, photo initiators, and grafted polymers.

vasantchemicals.com
4Catalysts and Polymers
TypeOne Time License
Description

Development and manufacturing of polymer and catalyst compounds with consistency in environment-friendly facilities. Manufacturing expertise supported by wide range of analytical and pilot plant scale testing activities.

vasantchemicals.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Custom Manufacturing - Quote-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing determined based on project scope, scale, complexity, and volume requirements. No standard pricing tiers published as each engagement is custom.

vasantchemicals.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vasant Chemicals manufactures chemical intermediates for the specialty chemicals and pharmaceutical industries, operating as a Contract Development and Manufacturing Organization (CDMO). The company produces specialty chemicals, pharmaceutical intermediates, catalysts, and polymers at commercial scale (>750,000 litres capacity), and offers custom synthesis and manufacturing services from kilograms to multi-tonne quantities with or without customer-provided know-how. It serves 18+ therapeutic areas including cancer treatment, CNS, anti-depressant, and anti-retroviral applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Production capacity growth from 50 tons/year in 1980 to 950+ tons/year currently
+1 more record
Product overview1 text field

Vasant Chemicals is a specialty fine chemicals CDMO (Contract Development and Manufacturing Organization) operating within the WeylChem Group. The company offers a portfolio of four interconnected product lines: Speciality Chemicals (including catalysts, polymers, cosmetic additives, and photo initiators), Pharma Intermediates (critical intermediates for 18+ therapeutic areas including anti-retrovirals and anti-hypertensives), Custom Manufacturing (scalable production from kilograms to multi-tonne), and Catalysts & Polymers. The company operates manufacturing facilities in Hyderabad and Visakhapatnam (SEZ), India, with capabilities spanning from kilo-lab and pilot-plant through 950+ metric tonnes of commercial production capacity.

Product and service2 records
1Speciality Chemicals
CategorySpecialty Chemicals
Description

Innovative specialty chemicals supplied to domestic and international clients serving dyestuff, agrochemicals, electronic applications, cosmetics, colour accelerators, dyes, pigments, catalysts, and polymers industries. Production scale capacity exceeds 750,000 litres from kilo-lab and pilot-plant through commercial manufacture.

2Pharma Intermediates
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Vasant Chemicals is a specialty fine chemicals CDMO operating within the WeylChem network. Ganesh Venkatraman was appointed as Managing Director with mandate to drive integration across the WeylChem CDMO network and strengthen the group's specialty chemicals capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Vasant Chemicals operates as a strategic partner for several global companies, providing custom manufacturing services with and without customer know-how and intellectual property. Co-development and scale-up of new products through collaborative customer partnerships.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Ganesh Venkatraman, current Managing Director of Vasant Chemicals, previously served as President at LAXAI Life Sciences, indicating industry connections and potential partnership networks.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Ganesh Venkatraman, current Managing Director of Vasant Chemicals, previously held leadership roles at Dr. Reddy's Laboratories, indicating pharmaceutical industry expertise and network connections.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian manufacturer of active pharmaceutical ingredients, intermediates, and specialty chemicals. Highly comparable business model spanning pharma intermediates and specialty chemistry with manufacturing scale similar to Vasant.

TypeDirect peer
Description

Indian pharmaceutical manufacturer producing APIs, intermediates and finished dosages. Comparable as an India-based intermediates manufacturer serving global generic and innovator pharma customers.

TypeBroad incumbent
Description

Global CDMO leader offering small-molecule API and intermediates manufacturing. Represents the upper-tier incumbent Vasant competes against for large multinational pharma outsourcing contracts.

TypeOthers
Description

Parent network of fine chemicals CDMOs under ICIG. Directly comparable as a sister CDMO platform with overlapping specialty fine chemicals capabilities, and the strategic integration counterparty for Vasant.

TypeBroad incumbent
Description

Global specialty chemicals manufacturer with significant pharmaceutical intermediates and API adjacencies. Comparable as a diversified specialty chemicals incumbent operating at much greater scale.

TypeBroad incumbent
Description

Major global CDMO with API and intermediates capabilities. Comparable as a large-scale contract manufacturer competing for outsourced small-molecule development and commercial supply work.

TypeDirect peer
Description

India-based CDMO providing API manufacturing and intermediates with a focus on complex chemistry. Comparable as a contract manufacturer of small-molecule intermediates serving global pharma customers.

TypeBroad incumbent
Description

Indian pharmaceutical company with CDMO services, APIs, and specialty chemicals. Comparable as an Indian-headquartered manufacturer serving pharma intermediates and custom synthesis markets.

TypeBroad incumbent
Description

Large-scale Indian CDMO with integrated drug substance and drug product capabilities. Overlaps with Vasant in API intermediates manufacturing but operates at significantly larger scale and broader scope.

TypeDirect peer
Description

India-based CDMO offering contract development and manufacturing services for small-molecule APIs and intermediates, with similar scale and customer profile. Directly comparable as an Indian-headquartered, privately held CDMO competing for similar pharma outsourcing contracts.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vasant Chemicals

Specialty Chemicalsvasantchemicals.com

Vasant Chemicals is an Indian specialty fine chemicals CDMO manufacturing pharmaceutical intermediates and specialty chemicals (catalysts, polymers, cosmetic additives, photo initiators) for global multinational clients across 18+ therapeutic areas, operating as part of the WeylChem Group following its 2024 ICIG acquisition.

What Vasant Chemicals does

Vasant Chemicals Private Limited is an Indian specialty fine chemicals Contract Development and Manufacturing Organization (CDMO) headquartered in Hyderabad, with manufacturing operations in Hyderabad (Jeedimetla Unit) and Visakhapatnam (Achutapuram SEZ Unit). Founded in 1980, the company operates four interconnected product lines: Specialty Chemicals (catalysts, cosmetic additives, photo initiators for UV curing and 3D printing, grafted polymers for food packaging), Pharmaceutical Intermediates (serving 18+ therapeutic areas including anti-retroviral, anti-hypertensive, anti-Alzheimer, anti-migraine, and anti-cancer applications), Custom Manufacturing (scale-up from kilograms to multi-tonne quantities, with or without customer IP), and Catalysts & Polymers. The company maintains 950+ metric tonnes/year of commercial production capacity, >400KL installed reactor capacity, and 750,000+ litres of total production scale.

The company's underlying technology centers on chemical synthesis with extensive reaction capabilities (Bechamp reduction, Bromination, Cyclisation, Chloro Sulphonation, Catalytic Hydrogenation, Grignard reaction, and over 15 other specialized reactions), supported by kilo-lab, pilot plant, and commercial-scale infrastructure including high vacuum distillation with De Dietrich columns, biological treatment plants, and Zero Liquid Discharge (ZLD) systems. Vasant Chemicals is ISO 9001, 14001, and 45001 certified across both manufacturing sites, GMP-compliant, and DSIR-recognized for R&D.

The business model is B2B enterprise field sales with quote-based, multi-year contracts. Pharma intermediates are supplied under long-term exclusive and non-exclusive agreements with strategic multinational clients, while custom manufacturing engagements span both proprietary process development and customer IP-based production. Revenue streams derive from custom manufacturing services, pharma intermediate sales, specialty chemical sales, and catalyst/polymer sales. The company sells globally, with historical recognition including a Best Quality Supplier Award from Sandoz Chemicals USA (now Clariant) and export awards from CHEMEXCIL and the President of India. In March 2024, Vasant Chemicals was acquired by International Chemical Investors Group (ICIG) and now operates as part of the WeylChem Group's CDMO network, with a new Managing Director appointed to drive integration.

Vasant Chemicals firmographics

Firmographics
Name
Vasant Chemicals
Legal name
Vasant Chemicals Pvt Limited
Website
https://vasantchemicals.com
Company type
Private
Founded year
1980
Operating status
Operating
Headcount range
101–250 employees
Short description
Vasant Chemicals is an Indian specialty fine chemicals CDMO manufacturing pharmaceutical intermediates and specialty chemicals (catalysts, polymers, cosmetic additives, photo initiators) for global multinational clients across 18+ therapeutic areas, operating as part of the WeylChem Group following its 2024 ICIG acquisition.
Ownership category
akta.pro rank

Vasant Chemicals industry classification

Industry
Product category
Specialty Chemicals
NAICS
Chemical Manufacturing (325), Medicinal and Botanical Manufacturing (325411), All Other Chemical Product and Preparation Manufacturing (32599)
SIC
Industrial Organic Chemicals (2860), Medicinal Chemicals & Botanical Products (2833), Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Specialty chemicals manufacturing
  • Pharmaceutical intermediates
  • Custom chemical synthesis
  • CDMO services
  • Catalysts and polymers

Where Vasant Chemicals is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices4 records

Markets served

Vasant Chemicals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Custom Manufacturing Services: Custom synthesis and manufacturing services for pharmaceutical intermediates and specialty chemicals. Operations conducted both with and without customer-provided know-how and intellectual property. Scale-up capabilities from kilograms to multi-tonne quantities.
  2. Pharmaceutical Intermediates: Manufacturing of pharma intermediates used in 18+ therapeutic areas including Cancer Treatment, CNS, Anti-depressant, and Anti-retroviral applications. Products supplied under long-term contractual agreements with strategic clients on exclusive/non-exclusive basis.
  3. Specialty Chemicals: Innovative specialty chemicals for dyestuff, agrochemicals, electronic applications, cosmetic industry, colour accelerator and other industries. Products include catalysts, cosmetic additives, photo initiators, and grafted polymers.
  4. Catalysts and Polymers: Development and manufacturing of polymer and catalyst compounds with consistency in environment-friendly facilities. Manufacturing expertise supported by wide range of analytical and pilot plant scale testing activities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Manufacturing - Quote-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Vasant Chemicals product offering

Product offering

Core offering

Vasant Chemicals manufactures chemical intermediates for the specialty chemicals and pharmaceutical industries, operating as a Contract Development and Manufacturing Organization (CDMO). The company produces specialty chemicals, pharmaceutical intermediates, catalysts, and polymers at commercial scale (>750,000 litres capacity), and offers custom synthesis and manufacturing services from kilograms to multi-tonne quantities with or without customer-provided know-how. It serves 18+ therapeutic areas including cancer treatment, CNS, anti-depressant, and anti-retroviral applications.

Product overview

Vasant Chemicals is a specialty fine chemicals CDMO (Contract Development and Manufacturing Organization) operating within the WeylChem Group. The company offers a portfolio of four interconnected product lines: Speciality Chemicals (including catalysts, polymers, cosmetic additives, and photo initiators), Pharma Intermediates (critical intermediates for 18+ therapeutic areas including anti-retrovirals and anti-hypertensives), Custom Manufacturing (scalable production from kilograms to multi-tonne), and Catalysts & Polymers. The company operates manufacturing facilities in Hyderabad and Visakhapatnam (SEZ), India, with capabilities spanning from kilo-lab and pilot-plant through 950+ metric tonnes of commercial production capacity.

Differentiator

Problem solved

Functional benefit

Products and services

  • Speciality Chemicals Innovative specialty chemicals supplied to domestic and international clients serving dyestuff, agrochemicals, electronic applications, cosmetics, colour accelerators, dyes, pigments, catalysts, and polymers industries. Production scale capacity exceeds 750,000 litres from kilo-lab and pilot-plant through commercial manufacture.
  • Pharma Intermediates

Quantifiable outcome

  • Production capacity growth from 50 tons/year in 1980 to 950+ tons/year currently
  • +1 more outcomes

Companies that use Vasant Chemicals

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Vasant Chemicals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vasant Chemicals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • WeylChem GroupcoreStrategic or Co-development PartnerVasant Chemicals is a specialty fine chemicals CDMO operating within the WeylChem network. Ganesh Venkatraman was appointed as Managing Director with mandate to drive integration across the WeylChem CDMO network and strengthen the group's specialty chemicals capabilities.
  • Strategic Partners (Multi-national Companies)coreStrategic or Co-development PartnerVasant Chemicals operates as a strategic partner for several global companies, providing custom manufacturing services with and without customer know-how and intellectual property. Co-development and scale-up of new products through collaborative customer partnerships.
  • LAXAI Life SciencesminorStrategic or Co-development PartnerGanesh Venkatraman, current Managing Director of Vasant Chemicals, previously served as President at LAXAI Life Sciences, indicating industry connections and potential partnership networks.
  • Dr. Reddy's LaboratoriesminorStrategic or Co-development PartnerGanesh Venkatraman, current Managing Director of Vasant Chemicals, previously held leadership roles at Dr. Reddy's Laboratories, indicating pharmaceutical industry expertise and network connections.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Vasant Chemicals competitors and assessment

Company assessment

Direct peers

  • Hikal Limited: Indian manufacturer of active pharmaceutical ingredients, intermediates, and specialty chemicals. Highly comparable business model spanning pharma intermediates and specialty chemistry with manufacturing scale similar to Vasant.
  • Granules India: Indian pharmaceutical manufacturer producing APIs, intermediates and finished dosages. Comparable as an India-based intermediates manufacturer serving global generic and innovator pharma customers.
  • Dishman Carbogen Amcis: India-based CDMO providing API manufacturing and intermediates with a focus on complex chemistry. Comparable as a contract manufacturer of small-molecule intermediates serving global pharma customers.
  • Sai Life Sciences: India-based CDMO offering contract development and manufacturing services for small-molecule APIs and intermediates, with similar scale and customer profile. Directly comparable as an Indian-headquartered, privately held CDMO competing for similar pharma outsourcing contracts.

Broad incumbents

  • Lonza Group: Global CDMO leader offering small-molecule API and intermediates manufacturing. Represents the upper-tier incumbent Vasant competes against for large multinational pharma outsourcing contracts.
  • Evonik Industries: Global specialty chemicals manufacturer with significant pharmaceutical intermediates and API adjacencies. Comparable as a diversified specialty chemicals incumbent operating at much greater scale.
  • Catalent: Major global CDMO with API and intermediates capabilities. Comparable as a large-scale contract manufacturer competing for outsourced small-molecule development and commercial supply work.
  • Jubilant Pharmova: Indian pharmaceutical company with CDMO services, APIs, and specialty chemicals. Comparable as an Indian-headquartered manufacturer serving pharma intermediates and custom synthesis markets.
  • Piramal Pharma Solutions: Large-scale Indian CDMO with integrated drug substance and drug product capabilities. Overlaps with Vasant in API intermediates manufacturing but operates at significantly larger scale and broader scope.

Others

  • WeylChem Group: Parent network of fine chemicals CDMOs under ICIG. Directly comparable as a sister CDMO platform with overlapping specialty fine chemicals capabilities, and the strategic integration counterparty for Vasant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Vasant Chemicals social profiles

Digital presence

Vasant Chemicals compliance and trust

Trust signal

Compliance7 records

Vasant Chemicals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vasant Chemicals leadership team

Management profile

Number of profiles

Profiles1 record

Vasant Chemicals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vasant Chemicals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vasant Chemicals

What does Vasant Chemicals do?

Vasant Chemicals manufactures chemical intermediates for the specialty chemicals and pharmaceutical industries, operating as a Contract Development and Manufacturing Organization (CDMO). The company produces specialty chemicals, pharmaceutical intermediates, catalysts, and polymers at commercial scale (>750,000 litres capacity), and offers custom synthesis and manufacturing services from kilograms to multi-tonne quantities with or without customer-provided know-how. It serves 18+ therapeutic areas including cancer treatment, CNS, anti-depressant, and anti-retroviral applications.

Is Vasant Chemicals a public or private company?

Vasant Chemicals is a private company. It is classified as corporate owned and is currently operating.

When was Vasant Chemicals founded?

Vasant Chemicals was founded in 1980. It employs 101 to 250 people.

Where is Vasant Chemicals based?

Vasant Chemicals is headquartered in Hyderabad, India, in the Asia region.

How does Vasant Chemicals make money?

Four revenue lines are on record. Custom Manufacturing Services are the primary driver. The others are pharmaceutical Intermediates, specialty Chemicals and catalysts and Polymers.

Who are Vasant Chemicals's main competitors?

Direct peers on record are Hikal Limited, Granules India, Dishman Carbogen Amcis and Sai Life Sciences. Broad incumbents are Lonza Group, Evonik Industries, Catalent, Jubilant Pharmova and Piramal Pharma Solutions. WeylChem Group is listed as an others.

Does Vasant Chemicals have an API?

No public API is recorded for Vasant Chemicals.

What industry is Vasant Chemicals in?

Vasant Chemicals's product category is Specialty Chemicals. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 325 and its SIC code is 2860.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TalkMarketsGLOBAL GLYOXAL MARKET SIZE, SHARE & FORECAST 2031 (CAGR 4.77%)The Global Glyoxal Market is projected to grow from USD 414.02 million in 2025 to USD 547.57 million by 2031, registering a CAGR of approximately 4.77%, driven by regulatory shifts away from formaldehyde and sustained demand from textiles, paper, and oil & gas sectors. Asia Pacific dominates the market due to strong industrial production in China and India, supported by established manufacturing infrastructure and access to raw materials. Recent market developments include a legal dispute involving Silver Fern Chemical over trade secrets, BASF SE reporting €11 billion in sales from recent product launches, ICIG acquiring a majority stake in Vasant Chemicals, and Hubei Hongyuan Pharmaceutical announcing a share repurchase program.TalkMarketsGLOBAL GLYOXAL MARKET SIZE, SHARE & FORECAST 2031 (CAGR 4.77%)TechSci Research projects the global glyoxal market to grow from USD 414.02 million in 2025 to USD 547.57 million by 2031, registering a CAGR of 4.77%, with Asia Pacific as the dominant regional market driven by textile and paper production in China and India. Key growth drivers include regulatory shifts away from formaldehyde toward glyoxal as a safer crosslinking agent, rising demand for crease-resistant textiles, and increasing adoption of fiber-based packaging as a plastic alternative. Recent market activity includes International Chemical Investors Group's majority stake acquisition of Vasant Chemicals in March 2024, BASF reporting approximately €11 billion in sales from products launched within five years, and Hubei Hongyuan Pharmaceutical announcing a share-repurchase program.openPR.comAn Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Production Chemicals MarketThe production chemicals market is projected to reach $9.59 billion by 2030, growing at a compound annual growth rate of 6.1%, driven by aging oilfield infrastructure, enhanced oil recovery projects, stricter environmental regulations, and increased offshore exploration activities. International Chemical Investors Group (ICIG) acquired Vasant Chemicals in March 2024, a move that strengthens WeylChem's global expansion while enhancing Vasant Chemicals' position in the specialty chemicals market. Swiss industrial engineering firm Sulzer Ltd. launched SULAC technology in December 2023, enabling polylactic acid producers to add lactic acid to lactide production capabilities.HrtodayGanesh Venkatraman Appointed as Managing Director of Vasant Chemicals (WeylChem Group)The WeylChem Group has appointed Ganesh Venkatraman as Managing Director of Vasant Chemicals (P) Ltd., a specialty fine chemicals CDMO operating within its network. Venkatraman brings nearly two decades of experience in the pharmaceutical CDMO ecosystem, having previously served as President at LAXAI Life Sciences and held leadership roles at Dr. Reddy's Laboratories. His mandate includes leading operations and P&L, driving integration across the WeylChem CDMO network, and strengthening the group's specialty chemicals capabilities.European-coatingsVasant Chemicals appoints Ganesh Venkatraman as new managing directorVasant Chemicals appointed Ganesh Venkatraman as its new managing director, aiming to strengthen its operations in the CDMO and specialty chemicals sectors.openPR.comEmerging Sub-Segments Transforming the Pharmaceutical Intermediates Market LandscapeThe pharmaceutical intermediates market is projected to grow to $49.52 billion by 2030 with a CAGR of 7.3%, driven by demand for complex drug development, contract manufacturing, and innovative synthesis methods. Key players include BASF SE, Lonza Group AG, and Vasant Chemicals, and recent acquisitions like ICIG's purchase of Vasant Chemicals aim to strengthen market positioning. The sector is also witnessing innovations in product lines such as API intermediates and targeted drug development, reflecting its evolving complexity.GlobeNewswireSpecialty Chemicals Market Size to Surpass USD 1.37 Trillion by 2035 Amid Sustainability and EV-Driven DemandPrecedence Research projects the global specialty chemicals market will grow from USD 940.72 billion in 2025 to approximately USD 1.38 trillion by 2035, driven by industrial expansion and electric vehicle demand. The report highlights significant private equity investments in Indian firms such as Vasant Chemicals and Porus Labs, reflecting confidence in the sector's growth. Key trends include a shift toward sustainability, digital transformation in manufacturing, and increased adoption of advanced materials for automotive applications.Ic-InvestorsInternational Chemical Investors Group (ICIG) announces acquisition of a majority stake in Vasant ChemicalsInternational Chemical Investors Group (ICIG) has closed the acquisition of a majority stake in Vasant Chemicals, an Indian specialty chemicals manufacturer, to integrate it into its WeylChem platform. This transaction aims to expand WeylChem's presence in the global specialty chemicals market and provide access to the fast-growing Indian market through Vasant Chemical's manufacturing facilities and expertise.